The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.

BACKGROUND: Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function. METHODS: Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months. RESULTS: In Group B, there was a significant increase post-treatment compared to baseline (p < 0.001) in total FSFI (20.3 (3.8) to 26.6 (4.2)) and all domains (desire: 3.0 (1.2) to 4.8 (1.2)), arousal: 3.0 (0.8) to 4.8 (0.9), lubrication: 3.9 (1.1) to 4.8 (1.2), orgasm: 3.6 (0.8) to 4.8 (1.0), satisfaction: 3.2 (0.4) to 4.0 (0.8) and pain: 3.2 (0.8) to 4.4 (1.2)). In Group A, there were no statistically significant changes in pre- and post-observation values. CONCLUSIONS: This study is one of the few demonstrating that management of OAB with mirabegron improves female sexual function. TRIAL REGISTRATION: TRN ISRCTN17199301 , 20/10/2017, retrospectively registered.

Translation and validation of the Greek version of the female sexual function index questionnaire.

The clinical evaluation of female sexual dysfunctions should be supplemented by validated questionnaires; however, there is no specific instrument available in Greek language. The study was designed to linguistically validate the Greek version of Female Sexual Function Index (FSFI). Ninety-nine healthy women and eighteen women with a sexual dysfunction were recruited through a survey and were asked to voluntarily complete the FSFI questionnaire in Greek (FSFI-Gr) at baseline and after 2 weeks. We assessed validity, internal consistency reliability and test-retest reliability of the FSFI greek version. Subscales of the FSFI showed good internal consistency reliability (Cronbach's=0.92, P<0.01). Test-retest reliability median 14 days apart was excellent with intraclass coefficient 0.91 (P<0.01). The FSFI-Gr discriminated between women with and without sexual dysfunction with an optimal cutoff score 26 (sensitivity 71.4%, specificity 92.2%). The Greek version of the FSFI is a reliable tool for the assessment of female sexual dysfunction. The results show that it is comparable to the outcome of studies in English-speaking countries.